Amoéba S.A. develops biological biocides for the prevention of microbiological risk for water treatment, human wounds, and plant protection. It develops applications by exploiting the characteristics of the amoeba Willaertia magna C2c Maky. The company was incorporated in 2010 and is based in Chassieu, France.
Stock data | 2024 | Change |
---|---|---|
Price | $0.5846393242191842 | N/A |
Market Cap | $29.01M | N/A |
Shares Outstanding | 49.62M | N/A |
Employees | 22.00 | N/A |